This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keith, E. R.
Right arrow Articles by Murdoch, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keith, E. R.
Right arrow Articles by Murdoch, D. R.

 Previous Article

Antimicrobial Agents and Chemotherapy, August 2008, p. 2998, Vol. 52, No. 8
0066-4804/08/$08.00+0     doi:10.1128/AAC.01526-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Antimicrobial Susceptibility Profile of Streptococcus pseudopneumoniae Isolated from Sputum{triangledown}


arrow
LETTER
 
Streptococcus pseudopneumoniae is a recently described member of the Streptococcus mitis/oralis group of viridans streptococci that shares some characteristics with Streptococcus pneumoniae (1). Key characteristics of S. pseudopneumoniae are the absence of pneumococcal capsule, insolubility in bile, resistance or indeterminate susceptibility to optochin when incubated in 5% CO2 but susceptibility to optochin when incubated in ambient air, and positive reactions in DNA probe hybridization and antigen detection tests (1, 3). The clinical relevance of S. pseudopneumoniae has not yet been established, although it may be associated with chronic obstructive pulmonary disease (3). As yet, the antibiotic susceptibility profile of S. pseudopneumoniae has not been reported in detail. The aim of this study was to determine the antibiotic susceptibility profile of a large number of S. pseudopneumoniae isolates recovered from clinical specimens.

Ninety-five isolates of S. pseudopneumoniae collected between 2000 and 2007 were studied. All isolates had been recovered as the predominant organism from good-quality sputum specimens containing >25 leukocytes and ≤10 squamous epithelial cells per 100x field. The isolates were identified on the basis of phenotypic characteristics as previously described (1, 3).

MICs were determined by broth microdilution with the MicroScan Micro STREP plus 1 system (Dade Behring, West Sacramento, CA). The MICs of penicillin, ampicillin, ceftriaxone, cefotaxime, cefepime, meropenem, chloramphenicol, clindamycin, erythromycin, azithromycin, tetracycline, vancomycin, gatifloxacin, levofloxacin, and trimethoprim-sulfamethoxazole were determined. Strains for which the MICs were greater than the highest dilution included on the MicroScan panel were retested with the Etest (AB Biodisk, Solna, Sweden) to determine the precise MIC. Susceptibility breakpoints were based on CLSI guidelines (2). Strains showing resistance to erythromycin but susceptibility to clindamycin were further tested to determine the presence of macrolide-lincosamide-streptogramin B resistance (MLS phenotype). Discs containing erythromycin (15 µg) and clindamycin (2 µg) were placed 20 mm apart on the plate. After incubation, the plates were examined for flattening of the clindamycin zone, which is indicative of the phenotype.

The MICs of the 15 antibiotics are shown in Table 1. No isolate was resistant to any β-lactam agent, although about one-third showed reduced susceptibility to penicillin and ampicillin. About one-third of the isolates were resistant to macrolides, almost half were resistant to tetracycline, and 71% were resistant to tetracycline and/or macrolide antibiotics. Reduced susceptibility to the macrolide antibiotics only (M phenotype) occurred in seven isolates, with an additional isolate being resistant to clindamycin (intrinsic MLS resistance). Inducible MLS resistance was noted in 3 of 28 erythromycin-resistant, clindamycin-susceptible isolates. In each case, the MIC was within a 1-dilution difference from susceptible. All azithromycin-resistant isolates were resistant to erythromycin.


View this table:
[in this window]
[in a new window]

  		TABLE 1. In vitro activities of antimicrobial agents against 95 isolates of S. pseudopneumoniae

One limitation of our study is that all of the isolates were collected from respiratory samples from patients attending a tertiary care center in one geographical area of New Zealand. As such, they may not be representative of the isolates found in the wider community or other regions of the world. Further studies are needed in other geographic regions, and possibly with other sample types, in order to better clarify the antibiotic susceptibility profile of S. pseudopneumoniae.


arrow
ACKNOWLEDGMENTS
 
We thank Roslyn Podmore and other staff of the Microbiology Unit, Canterbury Health Laboratories, for their support throughout this project.


arrow
FOOTNOTES
 
{triangledown} Published ahead of print on 2 June 2008. Back


arrow
REFERENCES
 
    1
  1. Arbique, J. C., C. Poyart, P. Trieu-Cuot, G. Quesne, M. da Glória, S. Carvalho, A. G. Steigerwalt, R. E. Morey, D. Jackson, R. J. Davidson, and R. R. Facklam. 2004. Accuracy of phenotypic and genotypic testing for identification of Streptococcus pneumoniae and a description of Streptococcus pseudopneumoniae sp. nov. J. Clin. Microbiol. 42:4686-4696.[Abstract/Free Full Text]
    2. 2
  2. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing. Seventeenth informational supplement. M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
    3. 3
  3. Keith, E. R., R. G. Podmore, T. P Anderson, and D. R. Murdoch. 2006. Characteristics of Streptococcus pseudopneumoniae isolated from purulent sputum samples. J. Clin. Microbiol. 44:923-927.[Abstract/Free Full Text]
Elaine R. Keith
Microbiology Unit
Canterbury Health Laboratories
P.O. Box 151
Christchurch, New Zealand

David R. Murdoch*
Department of Pathology
University of Otago, Christchurch
P.O. Box 4345
Christchurch, New Zealand

* Phone: 64 3 364 1530, Fax: 64 3 364 0238, E-mail: david.murdoch{at}cdhb.govt.nz

Antimicrobial Agents and Chemotherapy, August 2008, p. 2998, Vol. 52, No. 8
0066-4804/08/$08.00+0     doi:10.1128/AAC.01526-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keith, E. R.
Right arrow Articles by Murdoch, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keith, E. R.
Right arrow Articles by Murdoch, D. R.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»